ArticleNature medicine2023
Prevalence of smoldering multiple myeloma based on nationwide screening.
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Iceland Screens, Treats or Prevents Multiple Myeloma
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025.European journal of haematology · 2026Pooled it
- Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies.Blood cancer journal · 2025Pooled it
- Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.The oncologist · 2025Pooled it
- A prospective study of familial predisposition to plasma cell dyscrasias.Blood advances · 2026Article
- Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model.HemaSphere · 2026Article
- Characteristics and clinical course of younger patients with asymptomatic monoclonal gammopathies.British journal of haematology · 2026Article
- Article
- Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences.Future oncology (London, England) · 2026Article
- SECURE study: baseline findings from a UK prospective cohort of incidentally detected MGUS.Blood cancer journal · 2026Article
- Smoldering multiple myeloma: advances in diagnosis and risk stratification, and evolving therapeutic strategies.International journal of hematology · 2026Review
- CAR T cells take on precancers.Nature medicine · 2026Article
- Smoldering multiple myeloma in transition: redefining early myeloma in the modern era.Leukemia · 2026Review
- Diagnosis, risk stratification and management of smouldering multiple myeloma.Nature reviews. Clinical oncology · 2026Review
- Machine Learning Model Predicts Monoclonal Gammopathy Using Routine Laboratory Values.JCO clinical cancer informatics · 2026Article
- Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012-2022.American journal of hematology · 2026Article
- Review
- Why We Do Not Recommend That People With High-Risk Smoldering Myeloma Receive Treatment.American journal of hematology · 2026Article
- Prognosis and patterns of progression in smoldering multiple myeloma.Blood advances · 2026Article
- Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes.Cancers · 2026Article
- Smoldering multiple myeloma in the United States: a population-based analysis.Blood advances · 2026Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
22 authors at 5 institutions in 3 countries.
Funding
Abstract
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma. Here we define the epidemiological characteristics of SMM in the general population in Iceland. The iStopMM study (ClinicalTrials.gov ID: NCT03327597 ) is a nationwide screening study for multiple myeloma precursors where all residents in Iceland 40 years or older were invited to participate. SMM was defined as 10-60% bone marrow plasma cells and/or monoclonal (M) protein concentration ≥3 g dl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.